Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Shanghai Pharma Affiliate Hit with Allegations of Poor Quality

publication date: May 18, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Just before it completes its Hong Kong IPO, Shanghai Pharma faces allegations of substandard quality in one of its products. Anhui Huayuan Pharmaceutical filed a formal complaint with the Hong Kong Stock Exchange, alleging quality problems with an antibiotic produced by two of its affiliates. Anhui Huayuan Pharma has been distributing the antibiotic, known as Cefotiam, a third generation beta-lactam cephalosporin, for the companies since 2004. More details....

Stock Symbol: (SHA: 601607, HK: 2607)     Share this with colleagues:  


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...